Moderna Shares Jump as Much as 16% After Company Says Its Coronavirus Vaccine Trial Produced 'Robust' Immune Response
Vancouver, BC, July 15, 2020--Moderna's shares soared after the company said its potential vaccine to prevent Covid-19 produced a "robust" immune response in all 45 patients in its early stage human trial, according to newly released data published Tuesday evening in the peer-reviewed New England Journal of Medicine. The findings provide more promising data that the vaccine may give some protection against the coronavirus.